A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 16
- Registration Number
- NCT02161224
- Locations
- π§π¬
COMAC, Sofia, Bulgaria
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 44
- Registration Number
- NCT02155504
- Locations
- π¬π§
Parexel Early Phase Clinical Unit, Harrow, United Kingdom
A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 24
- Registration Number
- NCT02146742
- Locations
- π¬π§
Parexel Early Phase, Harrow, United Kingdom
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 28
- Registration Number
- NCT02138799
- Locations
- π©πͺ
Parexel International GmbH, Berlin, Germany
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 16
- Registration Number
- NCT02138162
- Locations
- π§π¬
Comac Medical Ltd., Sofia, Bulgaria
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT02136316
- Locations
- π¬π§
Site GB44001 Parexel Early Phase Clinical Unit, London, United Kingdom
An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 645
- Registration Number
- NCT02128334
- Locations
- π·πΊ
Site RU23 Private Practice, Anapa, Russian Federation
π·πΊSite RU26 Private Practice, Ekaterinburg, Russian Federation
π·πΊSite RU43 Private Practice, Ekaterinburg, Russian Federation
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 26
- Registration Number
- NCT02127034
- Locations
- π©πͺ
Parexel International GmbH, Berlin, Germany
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 30
- Registration Number
- NCT02124668
- Locations
- π¬πͺ
Site GE99502, Tbilisi, Georgia
π·πΊSite RU70002, Moscow, Russian Federation
π·πΊSite RU70003, Moscow, Russian Federation
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 215
- Registration Number
- NCT02116582
- Locations
- π©πͺ
Site DE49005, Nuertingen, Baden-Wuerttemberg, Germany
π¬π§Site GB44004, Birmingham, United Kingdom
π§πͺSite BE32001, Brussels, Flemish Brabant, Belgium
Β© Copyright 2024. All Rights Reserved by MedPath